London consortium secures £5 million to drive world-class university commercialisation
24 Apr 2018, 12:15 p.m.
The National Institute for Health Research (NIHR) GOSH Biomedical Research Centre (BRC) is part of a new £5 million consortium led by Kings College London which will strengthen London’s status as a world centre of commercialisation in medical technologies.The funds, which have been provided by Research England, will see the consortium of King’s, University College London, and Imperial College to bring together their collective expertise in cell and gene therapy to accelerate the progression to patient benefits.
Called Connecting Capabilities in Advanced Therapies, the consortium will create a strategic collaboration between London’s academic institutions, the NHS and industry in order to:
• Create a network to drive academic to academic, and academic to industry collaborations
• Provide a single, highly visible ‘front door’ for industry, and promote London’s strengths as a single entity
• Create new training opportunities in this rapidly growing sector
Principal investigator at UCL and director of the NIHR GOSH BRC Professor Thomas Voit said of the award, “This consortium will bring together world-class experts and cutting edge infrastructure in advanced therapies from across London, including the NIHR GOSH BRC’s own capability in cell and gene therapy for complex childhood conditions. We look forward to working with colleagues at Kings and Imperial as part of this exciting new collaboration to drive forward translation into new diagnostics and treatments for patients”.
Professor Simon Howell, Director of Academic Estates Strategy at King’s said: ‘Advanced Therapies are a field that London has exceptional expertise in, however this expertise is distributed across a wide range of academic leaders and multiple institutions.
“While substantial collaborations exist between the partners and with industry, there is a considerable untapped opportunity to deliver synergies and a ‘complete package’.
‘London Advanced therapies provides a vehicle to ensure that the potential of our expertise and capabilities can be unlocked. This award provides a vehicle for the wider London Advanced Therapies Community to engage with this ambition and maximise its achievements.’
Research England has invested £67 million in 14 collaborative projects between universities and other parties to drive forward world-class university commercialisation across the country.
David Sweeney, Executive Chair of Research England said: ‘These projects demonstrate the commitment of universities to work together to strengthen the R&D and technology capabilities of the UK, building upon our successful Higher Education Innovation Funding (HEIF).
‘In the Industrial Strategy, the Government asked us to improve our ability to turn exciting ideas into commercial products and services. Universities have stepped forward in these projects to that they can do world-class commercialisation, alongside world-class science.’
Other key partners and investors: Cell and Gene Therapy Catapult; MedCity; National Institute for Biological Standards and Control; NIHR CRN Industry partners; HE spinouts (e.g. Autolus, Orchard Therapeutics; GammaDelta Therapeutics; Leucid Bio).
Ancient gene mutation found as the cause of rare hereditary condition for GOSH patient.
UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).
Scientists build whole functioning thymus from human cells
Researchers from two leading national organisations have rebuilt a human thymus using human stem cells and a bioengineered scaffold thanks to support from the NIHR GOSH Biomedical Research Centre (BRC). Their work, which has been published in Nature Commu
Leukaemia trial shows promise and complexity of genome-edited cell therapies
A ‘one size fits all’ immune therapy developed at the UCL Great Ormond Street Institute of Child Health (ICH) could help to clear cancerous cells in children and adults who have exhausted all other treatment options for B-cell acute lymphoblastic leukaemi
GOSH researchers join experts in warning of the detrimental impact of a no deal Brexit on rare diseases
Experts have warned that a ‘no deal’ Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly spe